2 recruiting, 1 active not recruiting, 1 suspended, 1 withdrawn. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Metastatic Cancers: new trials by email Literature Review of Metastatic Cancers trials Research Report on Metastatic Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer REC-1245 - Unresectable, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 170 | 2024-11-21 | 2026-08-20 |
| Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers Psychoeducational Intervention, Open Label Placebo, Psychoeducational Intervention+Placebo - Metastatic Cancers, Fatigue | Phase 2 / Phase 3 | Recruiting | M.D. Anderson Cancer Center | 240 | 2024-02-16 | 2026-10-19 |
| Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Vemurafenib - Solid Tumors, Hematologic Cancers | Phase 2 | Active not recruiting | UNICANCER | 216 | 2014-10-13 | 2025-08-01 |
| Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas Gene Modified T Cells - Metastatic Cancers | Phase 2 | Suspended | Roger Williams Medical Center | 48 | 2012-10-01 | 2016-06-14 |
Neoplasms (5) · Colorectal Neoplasms (2) · Cholangiocarcinoma (1) · Duodenal Neoplasms (1) · Fatigue (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Pathological Conditions, Signs and Symptoms (2) · Rectal Diseases (2) · Adenocarcinoma (1) · Carcinoma (1) · Duodenal Diseases (1) · Endocrine Gland Neoplasms (1)
Cyclophosphamide (1) · Vemurafenib (1) · aldesleukin (1) · fludarabine (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Recursion Pharmaceuticals Inc. (1) · Roger Williams Medical Center (1) · UNICANCER (1)
United States (4) · Canada (1) · France (1)
Jean-Yves PI Blay, MD (1) · Nicholas D Klemen, M.D. (1) · Richard P Junghans, PhD, MD (1) · Sriram Yennu, MD (1)
2014 (1)